The Intervention Department of the Second Hospital of Shandong University, established in 2002, has now formed specialties with its own characteristics, academic styles, enjoyed high reputation both at home and abroad, and made outstanding contributions to the development of the interventional radiology in Shandong Province. In 2013, it was approved to establish the Institute of Intervention Oncology of Shandong University. In 2013 and 2017, it was respectively granted with the rights to award the master’s degree and the doctoral degree.
The Intervention Department consists of outpatient clinic, wards, and basic laboratories, etc.
Medical Members
The Intervention Department now owns 14 members devoted to medicine, teaching and research, including 3 chief physicians and 2 associate chief physicians. Among them, 71.45% are the young and middle-aged under the age of 45, and 71.45% are those with a master’s degree or a doctoral degree. It has 1 doctoral supervisor and 1 master’s supervisor.
Professor Li Yuliang, an academic leader and doctoral supervisor, has determined a number of stable research directions, and has trained 8 doctoral students and 8 masters.
Clinical Medicine
The Intervention Department is at the international advanced level and the domestic leading level in the field of iodine 125 radioactive seed implantation for the treatment of malignant tumors, as well as the minimally invasive treatment of cholelithiasis. It has carried out implantation of radioactive iodine 125 seeds earlier in China to treat pancreatic cancer/liver cancer/lung cancer, and accumulated rich clinical experience. In 2019, it became one of the first 6 “Training Bases of Tumor Radioactive Seed Implantation Therapy Technology” of the Chinese Medical Doctor Association. It was the first in China to carry out the percutaneous transhepatic duodenal papillary muscle dilatation to treat choledocholithiasis and other technologies, and it has carried out a number of multi-center studies. Up to now, it has published 11 papers (including 7 SCI papers).
The Intervention Department carries out comprehensive interventional treatment of neoplastic diseases and peripheral vascular diseases. At present, it has carried out endovascular stent-graft exclusion for the treatment of thoracic-abdominal aortic aneurysms and aortic dissection; percutaneous transhepatic duodenal papillary muscle dilatation anterograde lithotripsy for the treatment of choledocholithiasis/gallstone/calculus of intrahepatic duct; percutaneous transluminal angioplasty, intravascular stent implantation, catheter-direct thrombolysis and thrombosis removal for the treatment of peripheral vascular stenosis; transarterial embolization for the treatment of hemorrhinia, massive hemoptysis, massive hemorrhage of gastrointestinal tract, pelvic hemorrhage, traumatic hemorrhage and haemorrhoids; transjugular intrahepatic portosystemic shunt (TIPS) for the treatment of portal hypertension, hemorrhage from esophageal-fundic varices, refractory ascites, Budd-Chiari syndrome and other diseases; transarterial embolization, intravascular infusion chemotherapy, radioactive seeds interstitial brachytherapy, radiofrequency ablation, microwave ablation, absolute alcohol ablation and other methods for the treatment of various solid malignant tumors; CT-guided percutaneous catheter drainage for the treatment of hepatapostema, pulmonary abscess, pelvic abscess, psoas abscess, peripancreatic cyst and abscess, as well as hydropericardium and other body cavity effusion; stent implantation for the treatment of cavity tract stenosis or occlusion of various causes, such as esophageal obstruction, biliary tract obstruction, tracheal obstruction, ureteral obstruction; percutaneous ethanol injection for the treatment of treat maxillofacial angeiom, etc. It has carried out treatment projects comprehensively, and its technical level is in a leading position in China.
In recent years, it has carried out image-guided percutaneous gastrostomy, infusion port implantation, percutaneous transhepatic laser lithotripsy + papillary balloon dilatation and ultrasound-guided radioactive iodine 125 seeds interstitial brachytherapy for the treatment of prostatic cancer and other new technologies.
Scientific Research
The Intervention Department has undertaken 2 general projects of the National Natural Science Foundation of China, 2 sub-projects of the Special Important National Science and Technology Program, 4 provincial and ministerial-level projects, and 1 project of the “Shandong Provincial Implementation Plan of Special Disease Prevention and Control with Integrated Traditional Chinese and Western Medicines”. As of the end of 2019, its research funds are more than RMB 12 million Yuan. It has published more than 40 papers at home and abroad, of which 30 papers have been included in SCI. It has won 2 Shandong Science and Technology Progress Awards and leaded the compiling of 2 books. It has strong scientific research strength and good scientific research conditions. As the academic leader, Professor Li Yuliang is a famous interventional radiologist in China. He is also the Director-designate of the Interstitial Brachytherapy Society of the Tumor Minimally Invasive Therapy Professional Committee of China Anti-Cancer Association, the Director of the Comprehensive Intervention Branch of Shandong Provincial Medical Association, the Director of the Comprehensive Intervention Doctors Branch of Shandong Medical Doctor Association, a Standing Committee Member of the Intervention Doctors Branch of Chinese Medical Doctor Association, a Deputy Director of the Technical Expert Committee of Radioactive Seed Implantation Therapy of Chinese Medical Doctor Association, a Deputy Director of the Gastrointestinal and Pancreatic Intervention Professional Committee of the Intervention Group of the Radiology Branch of Chinese Medical Association, a Deputy Director of the Tumor Radioactive Seed Brachytherapy Professional Committee of the Intervention Doctors Branch of Chinese Medical Doctor Association, a Standing Committee Member of the Ablation Expert Committee of the Interventional Oncology Professional Committee of China Anti-Cancer Association, and a Committee Member of the Radiation Oncologists Branch of Chinese Medical Doctor Association. He is the Associate Editor-in-Chief in China Office of “Journal of Cancer Research and Therapeutics”, a reviewer of many SCI journals including “Asia-Pacific Journal of Clinical Oncology”, “Biomedical and Environmental Sciences”, “National Medical Journal of China”, “Chinese Journal of Lung Cancer”, and an Editorial Board Member of Surgery of “Shandong Medical Journal”. He has won 2 Shandong Science and Technology Progress Awards, and won the third “National Famous Doctor Outstanding Demeanor” Award in August 2019.
Academic Exchange and Cooperation
The Intervention Department now hires Professor Yancu Hertzanu from Ben-Gurion University (Israel) as a visiting professor. Personnels of the Intervention Department have been invited as the moderators or speakers in many international and domestic academic conferences, including World Congress of Brachytherapy, World Congress of Interventional Oncology, Annual Meeting of the Society of Gastrointestinal Intervention.
It has invited many experts from the UK, Greece, South Korea and other countries to our hospital for academic cooperations. Through such activities, we established good relations with them, and promoted academic development.